The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

Item
http://www.wikidata.org/entity/Q34636362
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practicePatterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOPAssessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient settingResults of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceThe incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma.An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
P2860

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

Item
http://www.wikidata.org/entity/Q34636362
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The need for improved neutrope ...... ndings from clinical practice.
@ast
The need for improved neutrope ...... ndings from clinical practice.
@en
The need for improved neutrope ...... ndings from clinical practice.
@nl
type
label
The need for improved neutrope ...... ndings from clinical practice.
@ast
The need for improved neutrope ...... ndings from clinical practice.
@en
The need for improved neutrope ...... ndings from clinical practice.
@nl
prefLabel
The need for improved neutrope ...... ndings from clinical practice.
@ast
The need for improved neutrope ...... ndings from clinical practice.
@en
The need for improved neutrope ...... ndings from clinical practice.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
The need for improved neutrope ...... indings from clinical practice
@en
P2093
P304
P31
P356
10.1016/J.LEUKRES.2012.02.002
P433
P478
P50
P577
P698